Patricia Martin Biography and Net Worth

Director of Cypherpunk Technologies

Ms. Martin joined BioCrossroads as the president and CEO in July 2019. A former Eli Lilly and Company executive, she was the chief operating officer (COO) of Lilly Diabetes for seven years, served as Lilly's Chief Diversity Officer (CDO) and Chief Alliance Officer (CAO). In her 26-year career with Lilly, her leadership roles also included clinical product development, finance, business development, human resources and investor relations.

Ms. Martin serves on the board of directors of CareSource, Inc., one of the nation's largest Medicaid managed care plans, where she chairs the Compensation Committee. She joined the board of Flame Biosciences, Inc. in 2020, and served as co-CEO in 2022. In 2021, she joined the board of AN2 Therapeutics, Inc. (NASDAQ: ANTX) and chairs the Compensation Committee. Within the Indiana life sciences sector, she serves on the boards of the Indiana Biosciences Research Institute, the Indiana Health Information Exchange and the Regenstrief Institute.

Ms. Martin holds an MBA from the Harvard Business School and a bachelor's degree in accounting from Indiana University.

What is Patricia A. Martin's net worth?: The estimated net worth of Patricia A. Martin is at least $489.25 thousand as of September 23rd, 2026. Ms. Martin owns 118,750 shares of Cypherpunk Technologies stock worth more than $489,250 as of September 28th. This net worth estimate does not reflect any other investments that Ms. Martin may own. Learn More about Patricia A. Martin's net worth.
How do I contact Patricia A. Martin?: The corporate mailing address for Ms. Martin and other Cypherpunk Technologies executives is 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA. Cypherpunk Technologies can also be reached via phone at (617) 714-0360 and via email at [email protected]. Learn More on Patricia A. Martin's contact information.
Has Patricia A. Martin been buying or selling shares of Cypherpunk Technologies?: Within the last three months, Patricia A. Martin has sold $193,000.00 of Cypherpunk Technologies stock. Most recently, Patricia A. Martin sold 50,000 shares of the business's stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $3.86, for a transaction totalling $193,000.00. Following the completion of the sale, the director now directly owns 118,750 shares of the company's stock, valued at $458,375. Learn More on Patricia A. Martin's trading history.
Who are Cypherpunk Technologies' active insiders?: Cypherpunk Technologies' insider roster includes Thomas Dietz (Director), and Patricia Martin (Director). Learn More on Cypherpunk Technologies' active insiders.
Are insiders buying or selling shares of Cypherpunk Technologies?: During the last twelve months, insiders at the sold shares 2 times. They sold a total of 70,000 shares worth more than $227,400.00. The most recent insider tranaction occured on September, 23rd when Director Patricia A. Martin sold 50,000 shares worth more than $193,000.00. Insiders at Cypherpunk Technologies own 3.5% of the company. Learn More about insider trades at Cypherpunk Technologies.
Information on this page was last updated on 9/23/2026.

Patricia A. Martin Insider Trading History at Cypherpunk Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/23/2026	Sell	50,000	$3.86	$193,000.00	118,750

Patricia A. Martin Buying and Selling Activity at Cypherpunk Technologies

Cypherpunk Technologies Company Overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Today's Range

Now: $4.12

$3.82

$4.19

50 Day Range

MA: $1.63

$0.59

$4.12

2 Week Range

Now: $4.12

$0.33

$4.19

Volume

19,703,109 shs

Average Volume

17,339,912 shs

Market Capitalization

$443.97 million

P/E Ratio

7.36

Dividend Yield

N/A

Beta

0.33